Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- How Unpopular Is Big Business?
- When Gallup asked Americans if the earth revolves around the sun, 79% said yes. Shocked that 21% disagreed? That lack of general knowledge may be alarming, but for folks in business it might be more shocking to know that more Americans believe big business is untrustworthy than have a...
- Blog posts 2008-01-16
- Covance Inc. Q3 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions. We'll take our first question today from Mr. Greg Bolan with Wells Fargo. Greg Bolan - Wells Fargo Just thinking about Early Development activity these days and I realize this is an overly simplistic analogy, but it would appear to me that pharma has been...
- Earnings calls 2009-10-22
- The 3Cs Of Successful Outsourcing:Communicate, Collaborate, Capitalize
- By sharing information, pharmaceutical companies can get more out of their relationships with vendors. During drug development, companies must efficiently transfer knowledge and processes internally between R&D and manufacturing functions. To realize exceptional returns on investment, Pharma companies must communicate closely with suppliers, giving them clear incentives to improve yield...
- White papers 2002-10-01
- Gaining A Competitive Edge From Strategic Outsourcing
- From the executive summary: ‘Outsourcing has been a useful tactic in the pharmaceutical industry for containing costs and meeting surges in product demand. Recently, volumes have grown rapidly for outsourcers, exceeding the industry's growth rate. More significant than volume growth is the change in how companies are viewing and using...
- White papers 2003-01-01
- Analytical Outsourcing
- Outsourcing is proving to be a scientifically and financially viable tool for pharmaceuticals and biopharmaceuticals companies. With the help of effective outsourcing technique, companies can reap huge benefits that outweigh the drawbacks of the organizations. However, the companies should keep in mind that the helping hand from outside should not...
- White papers 2003-01-01
- Key Considerations For Outsourcing Drug Development
- From the executive summary: ‘The considerable growth of the Contract Research Organization CRO industry in the last few years has been accompanied by a significant increase in the amount of outsourcing by pharmaceutical and biotechnology companies during the same period. While the pharmaceutical industry originally sought out CROs to handle...
- White papers 2003-01-01
- Regulating The Outsource Provider
- From the executive summary: ‘Excellence is never cheap, because it stems from a sound approach, experience, and time-intensive work. The cost to a product development program for truly outstanding consultation is worth avoiding the risk of failed clinical trial, major regulatory errors or even the loss of a small amount...
- White papers 2003-01-01
- Identifying And Selecting Outsourcing Providers
- From the executive summary: ‘The process of identifying and selecting an outsource provider is one of the most important steps in the research, development, and manufacturing of many pharmaceutical products. Yet, it seems to be one of the most overly simplified and typically one of the most rushed activities in...
- White papers 2003-01-01
- The Formula For Outsourcing Success
- Good project management at all levels of the organization results from effective communication and teamwork between the client and contractor. The appointment of an ombudsman by the client and the contractor culminates into an effective project management. Four factors are responsible for successful partnership between the client and the contractor....
- White papers 2003-01-01
- Rx for Pharmaceutical Companies: Internal Collaboration is the Key to Improved Innovation
- Research and development (R&D) budgets have nearly doubled over the past decade. However, the number of new chemical entities NCEs introduced to the market each year doesn't reflect that increased spending. Over the past decade, the number of NCEs introduced per year has varied little ? until dipping noticeably in...
- White papers 2002-09-12
- People - The Key to Optimizing the Pipeline
- The challenges currently facing the pharmaceutical industry are myriad. Whether it is the failure to meet R & D productivity goals, the scarcity of talent, changing demographics and skills requirements, or the advance of individualized medicine, it will be people, the industry's primary asset, who will shape the response to...
- White papers 2003-09-24
- The Cost of US Pharmaceutical Price Reduction: A Financial Simulation Model of R&D
- Some past empirical studies that have examined the links between pharmaceutical price controls, profits, cash flows, and investment in research and development (R&D) have been largely based on retrospective statistical analyses of firm- and/or industry-level data. These studies, which have contributed numerous insights and findings to the literature, relied upon...
- White papers 2005-02-01
- Health Care Distribution and Service Companies: Reflections on a Changing Business Model
- The pharmaceutical distribution sector is undergoing a change in the very structure of its core business model, shifting from a traditional "buy-and-hold" model to a fee-for-service model that is more akin to just-in-time inventory. Under the current traditional business model, distributors, to varying degrees, make a portion of their margin...
- White papers 2004-05-05
- Improving Logistics Performance in Danish Pharmaceutical Supply Chains
- Based on literature review and case studies, this article discusses how new types of delivery systems can improve logistics performance in pharmaceutical supply chains. Examples of Danish pharmaceutical companies are provided and benefits are described from a supply chain management point of view. The goal of logistics is to satisfy...
- White papers 2003-10-10
- Simulation of the Drug Development Process: A Case Study From the Pharmaceutical Industry
- This paper uses a case study from the pharmaceutical industry to show how simulation modeling can be applied to understanding large, highly-complex processes such as drug development. The paper concludes that simulation provides an enhanced resource planning capability compared with that provided by traditional spreadsheet analysis. This capability difference stems...
- White papers 2000-11-13
- Pharma Explores Uncharted Territory
- In an industry in which one incorrect data point can lead to grave consequences, pharmaceutical companies have not been eager to jump on the global outsourcing bandwagon. The risk is too great, the perceived reward too small. Today's push and pull dynamics, however, are changing attitudes and strategies. The article...
- White papers 2004-11-02
- Outsourcing Among Pharmaceutical and Biotech Firms: The Growing Imperative for a More Aggressive Approach to Outsourcing
- This report presents the findings of a research program conducted to explore outsourcing priorities and trends among senior finance executives at large pharmaceutical and biotechnology companies. Through a series of in-depth interviews with senior finance executives at pharma and biotech companies, it investigates and understands whether executives at such companies...
- White papers 2005-04-06
- Parallel Imports in Pharmaceuticals: Implications for Competition and Prices in Developing Countries
- Parallel imports PI, also called gray-market imports, are goods produced genuinely under protection of a trademark, patent, or copyright, placed into circulation in one market, and then imported into a second market without the authorization of the local owner of the intellectual property right. Regulation of PI in the pharmaceuticals...
- White papers 2001-04-01
- Pharmaceuticals, Prescription Plans, and Promoting Progress
- Monopoly response to buyers who pay fraction c of the product cost is to raise the buyer price for the initial quantity q0 from p0 to 1 c p0, and adjust to a different price and quantity only if profits are thereby raised further. A 25% prescription drug plan co-payment...
- White papers 2005-01-01
- R&D Outsourcing in Big Pharma - The Latest Trend: Is It for You?
- Expeditiously capitalizing on R&D expertise or intellectual property as coined by the Advantage Advocate committee is an important success factor in today's competitive business climate. Some pharmaceutical companies have taken the course of mergers and acquisitions to address filling their pipelines, while others have started taking a daring step in...
- White papers 2004-10-01
- << Previous
- page 1 of 4
- Next >>
Content Types
Refining Tags
- Research & Development (35 results)
- It Operations (19 results)
- Outsourcing (18 results)
- Outsourcing & Subcontracting (18 results)
- R&D (14 results)
- Biotechnology (10 results)
- Strategy (9 results)
- Management (9 results)
- Manufacturing (6 results)
- Product Development (6 results)
- Sales (6 results)
- Healthcare (5 results)
- Finance (5 results)
- Managed Hosting (5 results)
- John Maas (5 results)
- Seeking Alpha (5 results)
- Sales Strategy (5 results)
- Outsource (4 results)
- Human Resources (4 results)
- Intellectual Property (4 results)
- Call Transcript (4 results)
- Earnings (4 results)
- Quality (4 results)
- Pfizer Inc. (4 results)
- Benefits (3 results)
- Innovation (3 results)
- Product Marketing (3 results)
- Marketing (3 results)
- Government (3 results)
- Enterprise Software (3 results)
- Software (3 results)
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
